S&P 500 7,459.94 â–ŧ 73.83 (-0.98%) DOW 52,169.10 â–ŧ 383.87 (-0.73%) NASDAQ 25,535.42 â–ŧ 346.53 (-1.34%) US Markets Closed â€ĸ 07:20 AM ET

NCNA

NuCana plc

Price Chart
Latest Quote

$1.32

-0.03 (-2.07%)
Current Price
Previous Close $1.35
Open $1.35
Day High $1.39
Day Low $1.32
Volume 17,545
Fetched: 2026-07-16T16:14:54
Stock Information
Note: Financial values converted from GBP to USD
Shares Outstanding 4.16M
Total Debt $915K
Cash Equivalents $28.96M
Net Income $-41.36M
Sector Healthcare
Industry Biotechnology
Market Cap $5.47M
P/E Ratio 0.01
EPS (TTM) $132.01
Exchange NCM
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$-15.38M
Income$-41.36M
Book/sh$7.09
Cash/sh$5.17
Employees10
Financial Ratios
Quick Ratio5.29
Current Ratio5.48
Debt/Eq3.04
Returns & Margins
ROA-72.80%
ROE-231.68%
Ownership
Insider Ownership0.00%
Institutional Ownership1.38%
Insider & Institutional transactions data not available
Valuation Ratios
Forward P/E-0.14
P/B0.19
Analyst Data
Recommendationnone
Technical Indicators
SMA20$1.47
SMA50$1.81
SMA200$2.78
RSI33.09
ATR0.1261
Shares Float4.16M
Short Float2.78%
Short Ratio2.46
Volatility2.24
Rel Volume0.58
Performance History
Week-1.87%
Month-26.54%
Quarter-38.26%
6 Months-60.51%
YTD-63.87%
Year-86.85%
3 Years-99.97%
5 Years-99.99%
10 Years-100.00%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-07-17 $1.32 38,300
2026-07-16 $1.33 31,700
2026-07-15 $1.35 34,900
2026-07-14 $1.31 94,300
2026-07-13 $1.28 41,000
2026-07-10 $1.34 98,200
2026-07-09 $1.24 209,900
2026-07-08 $1.32 103,200
2026-07-07 $1.39 43,200
2026-07-06 $1.39 45,300
2026-07-02 $1.36 179,100
2026-07-01 $1.44 60,900
2026-06-30 $1.52 22,900
2026-06-29 $1.58 41,600
2026-06-26 $1.55 81,600
2026-06-25 $1.60 26,100
2026-06-24 $1.64 44,200
2026-06-23 $1.73 47,300
2026-06-22 $1.83 28,000
2026-06-18 $1.91 42,400
About NuCana plc

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. It has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.

Period:
Loading...
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Total Revenue $0 $0 $0 $0
Operating Revenue $0 $0 $0 $0
Expenses
Total Expenses $28,070,765 $30,997,358 $41,938,395 $58,905,086
Other Income Expense $-13,573,892 $264,094 $-2,235,367 $6,191,387
Other Non Operating Income Expenses $2,494,071 - - -
Net Non Operating Interest Income Expense $520,103 $482,376 $1,015,953 $901,423
Operating Expense $28,070,765 $30,997,358 $41,938,395 $58,905,086
General And Administrative Expense $10,908,699 $6,720,922 $8,169,397 $9,824,027
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-39,550,769 $-25,596,905 $-37,231,862 $-43,145,681
Net Interest Income $520,103 $482,376 $1,015,953 $901,423
Interest Income $520,103 $482,376 $1,015,953 $901,423
Normalized Income $-24,097,707 $-25,820,370 $-35,303,431 $-48,301,441
Net Income From Continuing And Discontinued Operation $-39,550,769 $-25,596,905 $-37,231,862 $-43,145,681
Total Operating Income As Reported $-27,096,582 $-30,733,264 $-44,173,762 $-52,713,699
Net Income Common Stockholders $-39,550,769 $-25,596,905 $-37,231,862 $-43,145,681
Net Income $-39,550,769 $-25,596,905 $-37,231,862 $-43,145,681
Net Income Including Noncontrolling Interests $-39,550,769 $-25,596,905 $-37,231,862 $-43,145,681
Net Income Continuous Operations $-39,550,769 $-25,596,905 $-37,231,862 $-43,145,681
Pretax Income $-41,124,554 $-30,250,888 $-43,157,808 $-51,812,276
Special Income Charges $1,133,179 $-44,465 $-677,751 $-393,446
Interest Income Non Operating $520,103 $482,376 $1,015,953 $901,423
Operating Income $-28,070,765 $-30,997,358 $-41,938,395 $-58,905,086
Per Share
Diluted EPS $0.00 $-1751.64 $-3570.66 $-4109.63
Basic EPS $0.00 $-1751.64 $-3570.66 $-4109.63
Other
Tax Effect Of Unusual Items $-614,901 $40,630 $-306,935 $1,035,628
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-11,633,610 $-30,558,100 $-38,928,262 $-64,110,163
Total Unusual Items $-16,067,963 $264,094 $-2,235,367 $6,191,387
Total Unusual Items Excluding Goodwill $-16,067,963 $264,094 $-2,235,367 $6,191,387
Reconciled Depreciation $369,193 $703,352 $774,766 $986,310
EBITDA (Bullshit earnings) $-27,701,573 $-30,294,006 $-41,163,629 $-57,918,776
EBIT $-28,070,765 $-30,997,358 $-41,938,395 $-58,905,086
Diluted Average Shares $5,607,916 $19,993 $14,168 $14,076
Basic Average Shares $5,607,916 $19,993 $14,168 $14,076
Diluted NI Availto Com Stockholders $-39,550,769 $-25,596,905 $-37,231,862 $-43,145,681
Tax Provision $-1,573,785 $-4,653,983 $-5,925,946 $-8,666,595
Other Special Charges $-1,133,179 - - -
Impairment Of Capital Assets $0 $44,465 $677,751 $393,446
Gain On Sale Of Security $-17,201,142 $308,559 $-1,557,616 $6,584,833
Research And Development $17,162,067 $24,276,436 $33,768,997 $49,081,059
Selling General And Administration $10,908,699 $6,720,922 $8,169,397 $9,824,027
Other Gand A $10,908,699 $6,720,922 $8,169,397 $9,824,027
Fetched: 2026-07-16
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $29,817,020 $5,059,556 $17,191,710 $48,691,655
Total Assets $40,198,878 $19,906,758 $37,473,050 $78,492,506
Total Non Current Assets $4,005,875 $3,380,673 $3,761,992 $4,492,293
Non Current Deferred Assets $157,648 $152,258 $192,681 $138,784
Non Current Deferred Taxes Assets $157,648 $152,258 $192,681 $138,784
Goodwill And Other Intangible Assets $2,961,625 $2,962,973 $2,867,306 $3,186,644
Other Intangible Assets $2,961,625 $2,962,973 $2,867,306 $3,186,644
Current Assets $36,193,003 $16,526,085 $33,711,058 $74,000,213
Prepaid Assets $1,005,174 $1,181,686 $2,653,067 $4,454,565
Receivables $2,511,588 $6,250,673 $7,848,712 $9,456,182
Other Receivables $55,244 $32,338 $52,549 $67,371
Taxes Receivable $2,456,344 $6,218,335 $7,796,162 $9,388,811
Cash Cash Equivalents And Short Term Investments $32,676,241 $9,093,726 $23,209,280 $56,472,996
Cash And Cash Equivalents $32,676,241 $9,093,726 $23,209,280 $56,472,996
Cash Financial $32,676,241 $9,093,726 $23,209,280 $56,472,996
Other Current Assets - - - $3,616,471
Other Non Current Assets - - - -
Debt
Total Debt $910,855 $256,009 $533,578 $861,000
Long Term Debt And Capital Lease Obligation $883,906 $157,648 $256,009 $533,578
Current Debt And Capital Lease Obligation $26,948 $98,362 $277,568 $327,423
Liabilities
Total Liabilities Net Minority Interest $7,420,233 $11,884,229 $17,414,034 $26,614,206
Total Non Current Liabilities Net Minority Interest $962,057 $207,502 $334,160 $595,559
Current Liabilities $6,458,176 $11,676,727 $17,079,874 $26,018,647
Payables And Accrued Expenses $6,431,228 $11,524,469 $16,802,306 $20,166,810
Payables $836,747 $3,825,321 $4,756,387 $6,689,932
Total Tax Payable $133,394 $180,554 $208,850 $218,282
Accounts Payable $703,352 $3,644,767 $4,547,537 $6,471,650
Equity
Common Stock Equity $32,778,645 $8,022,529 $20,059,016 $51,878,299
Total Equity Gross Minority Interest $32,778,645 $8,022,529 $20,059,016 $51,878,299
Stockholders Equity $32,778,645 $8,022,529 $20,059,016 $51,878,299
Gains Losses Not Affecting Retained Earnings $117,326,448 $105,665,891 $106,679,149 $102,231,321
Other Equity Adjustments $117,326,448 $105,665,891 $106,679,149 $102,231,321
Retained Earnings $-339,999,449 $-302,217,840 $-279,866,865 $-243,307,365
Other
Treasury Shares Number $673,709 $673,709 $673,709 $673,709
Ordinary Shares Number $28,039,579,376 $190,709,812 $70,551,274 $69,894,477
Share Issued $28,040,253,085 $191,383,521 $71,224,983 $70,568,186
Tangible Book Value $29,817,020 $5,059,556 $17,191,710 $48,691,655
Invested Capital $32,778,645 $8,022,529 $20,059,016 $51,878,299
Working Capital $29,734,827 $4,849,358 $16,631,184 $47,981,566
Capital Lease Obligations $910,855 $256,009 $533,578 $861,000
Total Capitalization $32,778,645 $8,022,529 $20,059,016 $51,878,299
Additional Paid In Capital $236,129,667 $196,919,795 $190,398,290 $190,131,501
Capital Stock $19,321,978 $7,654,683 $2,848,442 $2,822,841
Common Stock $19,321,978 $7,654,683 $2,848,442 $2,822,841
Long Term Capital Lease Obligation $883,906 $157,648 $256,009 $533,578
Long Term Provisions $78,150 $49,854 $78,150 $61,981
Current Capital Lease Obligation $26,948 $98,362 $277,568 $327,423
Current Accrued Expenses $5,594,481 $7,699,148 $12,045,920 $13,476,878
Net PPE $886,601 $265,441 $702,005 $1,166,864
Accumulated Depreciation $-1,366,282 $-1,259,836 $-2,387,625 $-1,928,156
Gross PPE $2,252,883 $1,525,278 $3,089,630 $3,095,020
Other Properties $1,474,076 $773,418 $1,802,846 $1,827,099
Machinery Furniture Equipment $778,808 $751,859 $1,286,784 $1,267,921
Current Provisions - $53,897 - $5,524,415
Fetched: 2026-07-16
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $-10,321,224 $-26,154,737 $-36,268,458 $-31,901,476
Operating Activities
Operating Cash Flow $-10,061,172 $-25,759,943 $-35,624,392 $-31,203,513
Cash Flow From Continuing Operating Activities $-10,061,172 $-25,759,943 $-35,624,392 $-31,203,513
Operating Gains Losses $261,399 $-497,197 $1,584,564 $-6,755,955
Investing Activities
Capital Expenditure $-260,052 $-394,794 $-644,066 $-697,963
Investing Cash Flow $214,240 $106,446 $3,891,344 $161,690
Cash Flow From Continuing Investing Activities $214,240 $106,446 $3,891,344 $161,690
Net Other Investing Changes - - $3,497,898 -
Financing Activities
Issuance Of Capital Stock $27,197,638 $11,761,614 $335,507 $0
Financing Cash Flow $33,693,542 $11,027,271 $-71,413 $-216,934
Cash Flow From Continuing Financing Activities $33,693,542 $11,027,271 $-71,413 $-216,934
Net Other Financing Charges $-1,813,625 $-443,301 $-48,507 -
Net Common Stock Issuance $27,197,638 $11,761,614 $335,507 $0
Common Stock Issuance $27,197,638 $11,761,614 $335,507 $0
Other
Repayment Of Debt $-72,761 $-300,474 $-363,803 $-305,864
End Cash Position $32,676,241 $9,093,726 $23,209,280 $56,472,996
Beginning Cash Position $9,093,726 $23,209,280 $56,472,996 $81,200,816
Effect Of Exchange Rate Changes $-264,094 $510,672 $-1,459,254 $6,530,937
Changes In Cash $23,846,609 $-14,626,226 $-31,804,462 $-31,258,757
Proceeds From Stock Option Exercised $8,382,289 $9,432 $5,390 $88,930
Net Issuance Payments Of Debt $-72,761 $-300,474 $-363,803 $-305,864
Net Long Term Debt Issuance $-72,761 $-300,474 $-363,803 $-305,864
Long Term Debt Payments $-72,761 $-300,474 $-363,803 $-305,864
Interest Received Cfi $474,291 $501,240 $1,037,512 $859,653
Net Intangibles Purchase And Sale $-260,052 $-389,404 $-638,676 $-681,794
Purchase Of Intangibles $-260,052 $-389,404 $-638,676 $-681,794
Net PPE Purchase And Sale $0 $-5,390 $-5,390 $-16,169
Purchase Of PPE $0 $-5,390 $-5,390 $-16,169
Taxes Refund Paid $5,373,504 $5,409,884 $7,538,805 $9,728,360
Change In Working Capital $-4,947,720 $-2,941,414 $-1,726,043 $5,016,438
Change In Payables And Accrued Expense $-5,094,589 $-5,281,880 $-3,388,757 $4,602,781
Change In Payable $-5,094,589 $-5,281,880 $-3,388,757 $4,602,781
Change In Account Payable $-2,941,414 $-902,770 $-1,924,113 $4,007,222
Change In Tax Payable $-2,153,174 $-4,379,109 $-1,464,644 $595,559
Change In Income Tax Payable $-2,153,174 $-4,379,109 $-1,464,644 $595,559
Change In Prepaid Assets $146,869 $2,340,466 $1,662,714 $413,657
Other Non Cash Items $16,548,992 $-459,470 $-976,878 $-873,127
Stock Based Compensation $13,511,911 $2,217,851 $5,196,992 $6,588,875
Provisionand Write Offof Assets $-53,897 $13,474 $-5,536,542 $5,524,415
Asset Impairment Charge $0 $44,465 $677,751 $393,446
Deferred Tax $-1,573,785 $-4,653,983 $-5,925,946 $-8,666,595
Deferred Income Tax $-1,573,785 $-4,653,983 $-5,925,946 $-8,666,595
Depreciation Amortization Depletion $369,193 $703,352 $774,766 $986,310
Depreciation And Amortization $369,193 $703,352 $774,766 $986,310
Amortization Cash Flow $262,747 $249,272 $280,263 $986,310
Amortization Of Intangibles $262,747 $249,272 $280,263 $986,310
Depreciation $106,446 $454,080 $494,503 -
Net Foreign Currency Exchange Gain Loss $261,399 $-497,197 $1,584,564 $-6,755,955
Net Income From Continuing Operations $-39,550,769 $-25,596,905 $-37,231,862 $-43,145,681
Fetched: 2026-07-16